PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells
Abstract The combination of PD-1 blockade with neoadjuvant chemotherapy (NAC) has achieved unprecedented clinical success in non-small cell lung cancer (NSCLC) compared to NAC alone, but the underlying mechanisms by which PD-1 blockade augments the effects of chemotherapy remain incompletely elucida...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-023-00384-x |
| _version_ | 1797419853519257600 |
|---|---|
| author | Zhenzhen Hui Yulin Ren Dong Zhang Yulong Chen Wenwen Yu Jie Cao Liang Liu Tao Wang Shanshan Xiao Liuqing Zheng Yue Pu Feng Wei Jian You Xiubao Ren |
| author_facet | Zhenzhen Hui Yulin Ren Dong Zhang Yulong Chen Wenwen Yu Jie Cao Liang Liu Tao Wang Shanshan Xiao Liuqing Zheng Yue Pu Feng Wei Jian You Xiubao Ren |
| author_sort | Zhenzhen Hui |
| collection | DOAJ |
| description | Abstract The combination of PD-1 blockade with neoadjuvant chemotherapy (NAC) has achieved unprecedented clinical success in non-small cell lung cancer (NSCLC) compared to NAC alone, but the underlying mechanisms by which PD-1 blockade augments the effects of chemotherapy remain incompletely elucidated. Single-cell RNA sequencing was performed on CD45+ immune cells isolated from surgically resected fresh tumors of seven NSCLC patients receiving NAC or neoadjuvant pembrolizumab and chemotherapy (NAPC). Multiplex fluorescent immunohistochemistry was performed on FFPE tissues before and after NAC or NAPC from 65 resectable NSCLC patients, and results were validated with GEO dataset. NAC resulted in an increase only of CD20+ B cells, whereas NAPC increased the infiltration of CD20+ B cells, CD4+ T cells, CD4+CD127+ T cells, CD8+ T cells, CD8+CD127+ and CD8+KLRG1+ T cells. Synergistic increase in B and T cells promotes favorable therapeutic response after NAPC. Spatial distribution analysis discovered that CD8+ T cells and their CD127+ and KLRG1+ subsets were in closer proximity to CD4+ T/CD20+ B cells in NAPC versus NAC. GEO dataset validated that B-cell, CD4, memory, and effector CD8 signatures correlated with therapeutic responses and clinical outcomes. The addition of PD-1 blockade to NAC promoted anti-tumor immunity through T and B cells recruitment in the tumor microenvironment and induced tumor-infiltrating CD8+ T cells skewed toward CD127+ and KLRG1+ phenotypes, which may be assisted by CD4+ T cells and B cells. Our comprehensive study identified key immune cell subsets exerting anti-tumor responses during PD-1 blockade therapy and that may be therapeutically targeted to improve upon existing immunotherapies for NSCLC. |
| first_indexed | 2024-03-09T06:54:14Z |
| format | Article |
| id | doaj.art-80b8b7de0c3b43cfb6226552570df70c |
| institution | Directory Open Access Journal |
| issn | 2397-768X |
| language | English |
| last_indexed | 2024-03-09T06:54:14Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj.art-80b8b7de0c3b43cfb6226552570df70c2023-12-03T10:14:29ZengNature Portfolionpj Precision Oncology2397-768X2023-05-017111710.1038/s41698-023-00384-xPD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cellsZhenzhen Hui0Yulin Ren1Dong Zhang2Yulong Chen3Wenwen Yu4Jie Cao5Liang Liu6Tao Wang7Shanshan Xiao8Liuqing Zheng9Yue Pu10Feng Wei11Jian You12Xiubao Ren13Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerWake Forest UniversityTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerDepartment of R&D, Hangzhou Repugene Technology Co., Ltd.Department of R&D, Hangzhou Repugene Technology Co., Ltd.Department of R&D, Hangzhou Repugene Technology Co., Ltd.Department of R&D, Hangzhou Repugene Technology Co., Ltd.Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for CancerAbstract The combination of PD-1 blockade with neoadjuvant chemotherapy (NAC) has achieved unprecedented clinical success in non-small cell lung cancer (NSCLC) compared to NAC alone, but the underlying mechanisms by which PD-1 blockade augments the effects of chemotherapy remain incompletely elucidated. Single-cell RNA sequencing was performed on CD45+ immune cells isolated from surgically resected fresh tumors of seven NSCLC patients receiving NAC or neoadjuvant pembrolizumab and chemotherapy (NAPC). Multiplex fluorescent immunohistochemistry was performed on FFPE tissues before and after NAC or NAPC from 65 resectable NSCLC patients, and results were validated with GEO dataset. NAC resulted in an increase only of CD20+ B cells, whereas NAPC increased the infiltration of CD20+ B cells, CD4+ T cells, CD4+CD127+ T cells, CD8+ T cells, CD8+CD127+ and CD8+KLRG1+ T cells. Synergistic increase in B and T cells promotes favorable therapeutic response after NAPC. Spatial distribution analysis discovered that CD8+ T cells and their CD127+ and KLRG1+ subsets were in closer proximity to CD4+ T/CD20+ B cells in NAPC versus NAC. GEO dataset validated that B-cell, CD4, memory, and effector CD8 signatures correlated with therapeutic responses and clinical outcomes. The addition of PD-1 blockade to NAC promoted anti-tumor immunity through T and B cells recruitment in the tumor microenvironment and induced tumor-infiltrating CD8+ T cells skewed toward CD127+ and KLRG1+ phenotypes, which may be assisted by CD4+ T cells and B cells. Our comprehensive study identified key immune cell subsets exerting anti-tumor responses during PD-1 blockade therapy and that may be therapeutically targeted to improve upon existing immunotherapies for NSCLC.https://doi.org/10.1038/s41698-023-00384-x |
| spellingShingle | Zhenzhen Hui Yulin Ren Dong Zhang Yulong Chen Wenwen Yu Jie Cao Liang Liu Tao Wang Shanshan Xiao Liuqing Zheng Yue Pu Feng Wei Jian You Xiubao Ren PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells npj Precision Oncology |
| title | PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells |
| title_full | PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells |
| title_fullStr | PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells |
| title_full_unstemmed | PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells |
| title_short | PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells |
| title_sort | pd 1 blockade potentiates neoadjuvant chemotherapy in nsclc via increasing cd127 and klrg1 cd8 t cells |
| url | https://doi.org/10.1038/s41698-023-00384-x |
| work_keys_str_mv | AT zhenzhenhui pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT yulinren pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT dongzhang pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT yulongchen pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT wenwenyu pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT jiecao pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT liangliu pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT taowang pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT shanshanxiao pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT liuqingzheng pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT yuepu pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT fengwei pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT jianyou pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells AT xiubaoren pd1blockadepotentiatesneoadjuvantchemotherapyinnsclcviaincreasingcd127andklrg1cd8tcells |